Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial

Christina Davies, Hongchao Pan, Jon Godwin, Richard Gray, Rodrigo Arriagada, Vinod Raina, Mirta Abraham, Victor Hugo Medeiros Alencar, Atef Badran, Xavier Bonfill Cosp, Joan Caroline Bradbury, Michael Clarke, Rory Collins, Susan Ruth Davis, Antonella Delmestri, John Forbes, Peiman Haddad, Ming-Feng Hou, Moshe Inbar, Hussein KhaledJoanna Kielanowska, Wing-Hong Kwan, Beela Mathew, Indraneel Mittra, Bettina Muller, Antonio Nicolucci, Octavio Peralta, Fany Pernas, Lubos Petruzelka, Tadeusz Pienkowski, Ramachandran Radhika, Balakrishnan Rajan, Maryna Rubach, Sera Tort, Gerard Urrutia, Miriam Valentini, Yaochen Wang, Richard Peto

Research output: Contribution to journalArticleResearchpeer-review

1121 Citations (Scopus)

Abstract

For women with oestrogen receptor (ER)-positive early breast cancer, treatment with tamoxifen for 5 years substantially reduces the breast cancer mortality rate throughout the first 15 years after diagnosis. The study aimed to assess the further effects of continuing tamoxifen to 10 years instead of stopping at 5 years.
Original languageEnglish
Pages (from-to)805 - 816
Number of pages12
JournalThe Lancet
Volume381
Issue number9869
DOIs
Publication statusPublished - 2013

Cite this